以RA Capital Management为首的RA Capital Management B系列集资144M系列B, 以推进针对抗白金氏抗卵巢癌的细胞治疗。 Outpace Bio raises $144M Series B funding, led by RA Capital Management, to advance their cell therapy targeting platinum-resistant ovarian cancer.
以西雅图为基地的一家细胞治疗公司,利用人工智能进行蛋白质设计,以固态肿瘤为对象。 该公司在RA Capital Management领导的B系列中筹集了144M美元的资金。 Outpace Bio, a Seattle-based cell therapy company using AI for protein design to target solid tumors, raised $144M in Series B funding led by RA Capital Management. 资金将用于推进其编入方案的T型细胞产品候选产品,主要方案OPB-101针对抗白金素的卵巢、输卵管或主要腹膜癌。 Funds will be used to advance their programmed T cell product candidates, with lead program OPB-101 targeting platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. 2025年,该治疗正在顺利进行,以通过IND处理,并首次施药。 The treatment is on track for IND clearance and first dosing in 2025.